Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept
- Conditions
- First Posted Date
- 2002-04-22
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 36
- Registration Number
- NCT00034060
- Locations
- 🇺🇸
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States
Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury
- First Posted Date
- 2002-03-08
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- National Institute of Nursing Research (NINR)
- Target Recruit Count
- 27
- Registration Number
- NCT00031551
- Locations
- 🇺🇸
Greenville Cancer Centers of the Carolinas, Greenville, South Carolina, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
- Conditions
- First Posted Date
- 2002-01-11
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 15
- Registration Number
- NCT00029328
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Etanercept for Wegener's Granulomatosis
- Conditions
- First Posted Date
- 2000-03-27
- Last Posted Date
- 2007-12-28
- Target Recruit Count
- 181
- Registration Number
- NCT00005007
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Boston University, Boston, Massachusetts, United States
🇺🇸Beth Israel Medical Center, New York, New York, United States
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 150
- Registration Number
- NCT00001955
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Etanercept Therapy for Sjogren's Syndrome
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 28
- Registration Number
- NCT00001954
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Etanercept to Treat Wegener's Granulomatosis
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 60
- Registration Number
- NCT00001901
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.